dobutamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
dopaminergic agents dopamine derivatives used as cardiac stimulant/antihypertensives/diuretics 937 34368-04-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • dobutamine
  • dobutamine hydrochloride
  • dobutamine HCl
A catecholamine derivative with specificity for BETA-1 ADRENERGIC RECEPTORS. It is commonly used as a cardiotonic agent after CARDIAC SURGERY and during DOBUTAMINE STRESS ECHOCARDIOGRAPHY.
  • Molecular weight: 301.39
  • Formula: C18H23NO3
  • CLOGP: 2.43
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 4
  • TPSA: 72.72
  • ALOGS: -4.34
  • ROTB: 7
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.50 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.13 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
CL (Clearance) 115 mL/min/kg Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
July 18, 1978 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Stress cardiomyopathy 132.92 29.88 38 2726 7849 50594511
Cardiogenic shock 85.06 29.88 32 2732 15567 50586793
Multiple organ dysfunction syndrome 78.29 29.88 43 2721 50294 50552066
Local anaesthetic systemic toxicity 58.66 29.88 12 2752 600 50601760
Drug ineffective 58.07 29.88 133 2631 819200 49783160
Cardiac failure 50.48 29.88 38 2726 76002 50526358
Status epilepticus 37.24 29.88 17 2747 13389 50588971
Ureaplasma infection 37.20 29.88 8 2756 510 50601850
Pulmonary hypertension 34.67 29.88 22 2742 33395 50568965
Ventricular tachycardia 34.56 29.88 17 2747 15804 50586556
Renal failure 31.96 29.88 34 2730 106599 50495761

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Appendicolith 329.22 28.68 80 4067 3400 29566980
Multiple organ dysfunction syndrome 271.58 28.68 145 4002 62971 29507409
Appendicitis 264.33 28.68 82 4065 8697 29561683
Stress 236.87 28.68 95 4052 21395 29548985
Ascites 168.00 28.68 88 4059 36531 29533849
Abdominal distension 138.94 28.68 84 4063 45827 29524553
Ventricular fibrillation 130.58 28.68 57 4090 15776 29554604
Sepsis 110.79 28.68 117 4030 142565 29427815
General physical health deterioration 103.13 28.68 97 4050 102760 29467620
Hyponatraemia 102.84 28.68 81 4066 67552 29502828
Toxic epidermal necrolysis 81.30 28.68 43 4104 18110 29552270
Constipation 66.85 28.68 81 4066 114079 29456301
Off label use 62.93 28.68 133 4014 300667 29269713
Cardiogenic shock 62.81 28.68 37 4110 19153 29551227
Abdominal pain 60.44 28.68 84 4063 135273 29435107
Drug ineffective 51.43 28.68 138 4009 363032 29207348
Stress cardiomyopathy 39.83 28.68 13 4134 1611 29568769
Vomiting 36.48 28.68 87 4060 212173 29358207
Fear 35.55 28.68 20 4127 9484 29560896
Anhedonia 32.04 28.68 17 4130 7183 29563197
Injury 31.42 28.68 24 4123 19022 29551358

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Appendicolith 353.81 25.84 80 6557 3389 64488706
Multiple organ dysfunction syndrome 308.35 25.84 167 6470 101246 64390849
Appendicitis 253.87 25.84 82 6555 13487 64478608
Stress 178.93 25.84 98 6539 60436 64431659
Ascites 171.26 25.84 96 6541 61905 64430190
Ventricular fibrillation 163.97 25.84 69 6568 23791 64468304
Stress cardiomyopathy 149.17 25.84 50 6587 9207 64482888
Cardiogenic shock 128.66 25.84 64 6573 32363 64459732
Abdominal distension 123.69 25.84 92 6545 95902 64396193
Sepsis 115.82 25.84 130 6507 230211 64261884
Drug ineffective 108.34 25.84 254 6383 839993 63652102
General physical health deterioration 78.98 25.84 101 6536 204324 64287771
Off label use 76.53 25.84 187 6450 632619 63859476
Hyponatraemia 73.16 25.84 83 6554 148256 64343839
Toxic epidermal necrolysis 72.37 25.84 46 6591 37120 64454975
Ventricular tachycardia 55.96 25.84 38 6599 34227 64457868
Fatigue 51.29 25.84 8 6629 748722 63743373
Constipation 50.41 25.84 87 6550 229250 64262845
Local anaesthetic systemic toxicity 49.73 25.84 12 6625 673 64491422
Cardiac failure 42.75 25.84 60 6577 132313 64359782
Right ventricular failure 40.35 25.84 26 6611 21445 64470650
Abdominal pain 37.16 25.84 92 6545 312283 64179812
Fear 36.86 25.84 24 6613 20147 64471948
Hypernatraemia 36.66 25.84 20 6617 12169 64479926
Renal impairment 33.32 25.84 54 6583 134963 64357132
Status epilepticus 32.94 25.84 23 6614 21640 64470455
Renal failure 31.17 25.84 62 6575 181626 64310469
Electrocardiogram ST segment elevation 30.76 25.84 15 6622 7244 64484851
Ventricular arrhythmia 30.46 25.84 15 6622 7400 64484695
Torsade de pointes 30.12 25.84 20 6617 17343 64474752
Renal injury 29.77 25.84 19 6618 15410 64476685
Cardiomyopathy 29.70 25.84 23 6614 25333 64466762
Ureaplasma infection 29.34 25.84 8 6629 730 64491365
Anhedonia 29.27 25.84 18 6619 13688 64478407
Eosinophilic myocarditis 28.20 25.84 8 6629 844 64491251
Cardiac arrest 28.15 25.84 54 6583 154010 64338085
Arthralgia 27.47 25.84 6 6631 442254 64049841

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C01CA07 CARDIOVASCULAR SYSTEM
CARDIAC THERAPY
CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
Adrenergic and dopaminergic agents
FDA MoA N0000000245 Adrenergic beta-Agonists
FDA EPC N0000175555 beta-Adrenergic Agonist
CHEBI has role CHEBI:35522 beta-adrenergic agonists
CHEBI has role CHEBI:35524 sympathomimetic
CHEBI has role CHEBI:38147 cardiotonic drugs
MeSH PA D018663 Adrenergic Agents
MeSH PA D000322 Adrenergic Agonists
MeSH PA D058665 Adrenergic beta-1 Receptor Agonists
MeSH PA D000318 Adrenergic beta-Agonists
MeSH PA D002316 Cardiotonic Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D020011 Protective Agents
MeSH PA D013566 Sympathomimetics

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Cardiogenic shock indication 89138009
Decompensated cardiac failure indication 195111005
Stress echocardiography using dobutamine indication 703338002
Cardiac Decompensation indication
Cardiac Decompensation Post Cardiac Surgery indication
Organic Cardiac Disease indication
Ventricular premature beats contraindication 17338001
Myocardial infarction contraindication 22298006 DOID:5844
Hypovolemia contraindication 28560003
Hypertensive disorder contraindication 38341003 DOID:10763
Hypokalemia contraindication 43339004
Atrial fibrillation contraindication 49436004 DOID:0060224
Aortic valve stenosis contraindication 60573004 DOID:1712
Idiopathic hypertrophic subaortic stenosis contraindication 360465008




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.98 acidic
pKa2 10.59 acidic
pKa3 13.49 acidic
pKa4 9.03 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Beta-2 adrenergic receptor GPCR AGONIST EC50 6.20 WOMBAT-PK CHEMBL
Beta-1 adrenergic receptor GPCR AGONIST EC50 5.50 WOMBAT-PK CHEMBL
Tyrosine-protein kinase Fyn Kinase IC50 5.40 DRUG MATRIX
Catechol O-methyltransferase Enzyme Km 4.30 WOMBAT-PK
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 5.98 DRUG MATRIX
Sodium-dependent serotonin transporter Transporter Ki 6.00 DRUG MATRIX
Sodium-dependent noradrenaline transporter Transporter Ki 6.42 DRUG MATRIX
Alpha-2B adrenergic receptor GPCR Ki 5.87 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 5.77 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Ki 6.91 DRUG MATRIX
Carbonic anhydrase 2 Enzyme Ki 6.32 CHEMBL
Alpha-1D adrenergic receptor GPCR Ki 7.35 DRUG MATRIX
Carbonic anhydrase 1 Enzyme Ki 5.72 CHEMBL
Carbonic anhydrase 4 Enzyme Ki 5.05 CHEMBL
Carbonic anhydrase 9 Enzyme Ki 5.01 CHEMBL
Carbonic anhydrase 12 Enzyme Ki 5.36 CHEMBL
Epidermal growth factor receptor Kinase IC50 5.26 DRUG MATRIX
Carbonic anhydrase 5A, mitochondrial Enzyme Ki 6.14 CHEMBL
Carbonic anhydrase 5B, mitochondrial Enzyme Ki 6.05 CHEMBL
Carbonic anhydrase 3 Enzyme Ki 5.13 CHEMBL
Carbonic anhydrase 6 Enzyme Ki 5.02 CHEMBL
Carbonic anhydrase 14 Enzyme Ki 4.92 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 5.38 CHEMBL
Carbonic anhydrase 13 Enzyme Ki 5.02 CHEMBL
Carbonic anhydrase 7 Enzyme Ki 5.37 CHEMBL
Tyrosine-protein kinase Lck Kinase IC50 5.26 DRUG MATRIX
Arachidonate 15-lipoxygenase Enzyme IC50 6.22 DRUG MATRIX
Alpha-1B adrenergic receptor GPCR Ki 6.73 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor Ki 5.80 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR IC50 6.96 CHEMBL
Carbonic anhydrase 15 Enzyme Ki 6.41 CHEMBL

External reference:

IDSource
4019730 VUID
N0000147822 NUI
D00632 KEGG_DRUG
49745-95-1 SECONDARY_CAS_RN
203121 RXNORM
4017541 VANDF
4019730 VANDF
C0012963 UMLSCUI
CHEBI:4670 CHEBI
Y00 PDB_CHEM_ID
CHEMBL926 ChEMBL_ID
DB00841 DRUGBANK_ID
CHEMBL1200418 ChEMBL_ID
D004280 MESH_DESCRIPTOR_UI
36811 PUBCHEM_CID
535 IUPHAR_LIGAND_ID
3340 INN_ID
3S12J47372 UNII
2871 MMSL
4625 MMSL
d00215 MMSL
000614 NDDF
000615 NDDF
26523005 SNOMEDCT_US
387145002 SNOMEDCT_US
90118002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Dobutamine Hydrochloride in Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0338-1073 INJECTION 100 mg INTRAVENOUS NDA 18 sections
Dobutamine Hydrochloride in Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0338-1075 INJECTION 200 mg INTRAVENOUS NDA 18 sections
Dobutamine Hydrochloride in Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0338-1077 INJECTION 400 mg INTRAVENOUS NDA 18 sections
DOBUTAMINE HUMAN PRESCRIPTION DRUG LABEL 1 0409-2344 INJECTION, SOLUTION, CONCENTRATE 12.50 mg INTRAVENOUS ANDA 21 sections
DOBUTAMINE HUMAN PRESCRIPTION DRUG LABEL 1 0409-2344 INJECTION, SOLUTION, CONCENTRATE 12.50 mg INTRAVENOUS ANDA 21 sections
Dobutamine in Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0409-2346 INJECTION, SOLUTION 100 mg INTRAVENOUS NDA 12 sections
Dobutamine in Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0409-2347 INJECTION, SOLUTION 200 mg INTRAVENOUS NDA 12 sections
Dobutamine in Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0409-3724 INJECTION, SOLUTION 400 mg INTRAVENOUS NDA 12 sections
Dobutamine Hydrochloride in Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 50090-4562 INJECTION 400 mg INTRAVENOUS NDA 18 sections
DOBUTAMINE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1330 INJECTION, SOLUTION 200 mg INTRAVENOUS NDA 12 sections
DOBUTAMINE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1337 INJECTION, SOLUTION, CONCENTRATE 12.50 mg INTRAVENOUS ANDA 12 sections
DOBUTAMINE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1337 INJECTION, SOLUTION, CONCENTRATE 12.50 mg INTRAVENOUS ANDA 12 sections
DOBUTAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1566 INJECTION 100 mg INTRAVENOUS NDA 11 sections
Dobutamine HUMAN PRESCRIPTION DRUG LABEL 1 54868-5717 INJECTION, SOLUTION 12.50 mg INTRAVENOUS ANDA 11 sections
Dobutamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 54868-5777 INJECTION, SOLUTION 400 mg INTRAVENOUS NDA 12 sections